title: High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
abstract: This paper demonstrates and characterizes naturally occurring antibodies to interferon (IFN) in human IgG preparations. In vitro neutralization of the antiviral effect of IFN alpha and IFN beta, but not IFN gamma, was observed in 12 of 15 normal IgG preparations. The neutralizing capacity was higher against rIFN alpha 2A and rIFN alpha 2C than against lymphoblastoid IFN alpha and IFN beta. Frühsommer meningoencephalitis hyperimmune IgG and hepatitis-B hyperimmune IgG showed potent neutralization, whereas anti-rhesus D-, anti-rabies-, and anti-tetanus IgG showed weak neutralization. Saturable binding of 125I-rIFN alpha 2A was demonstrated only in those IgG preparations found to neutralize the antiviral effect of IFN. Significant correlation between IFN binding and neutralization capacity was observed. The antibodies bound with Fab to rIFN alpha 2A with an avidity of approximately 30 pM; the majority was of the IgG1 subclass. Maximum binding capacity was 490 pg rIFN alpha 2A/mg IgG. Cross-binding of rIFN alpha 2C, lyIFN alpha N1 and IFN beta occurred with 10 and 100-200 times lower activities than that of rIFN alpha 2A. There was no cross-binding with rIFN gamma or rIL-6. IgG preparations containing anti-IFN antibodies blocked the binding of 125I-rIFN alpha 2A to A549 cells. In conclusion, pharmaceutically prepared human IgG preparations contain variable but significant levels of high-avidity IFN alpha and IFN beta neutralizing antibodies.
authors.affiliation: Department of Dermatology, Rigshospitalet, Copenhagen, Denmark.
authors.forename: C
authors.initials: C
authors.lastname: Ross
authors.forename: M
authors.initials: M
authors.lastname: Svenson
authors.forename: M B
authors.initials: MB
authors.lastname: Hansen
authors.forename: G L
authors.initials: GL
authors.lastname: Vejlsgaard
authors.forename: K
authors.initials: K
authors.lastname: Bendtzen
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000936:Antigen-Antibody Complex; D001667:Binding, Competitive; D002460:Cell Line; D004686:Encephalomyocarditis virus / Q000187:drug effects*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D007074:Immunoglobulin G / Q000145:classification / Q000494:pharmacology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology* / Q000494:pharmacology; D016899:Interferon-beta / Q000276:immunology* / Q000494:pharmacology; D007371:Interferon-gamma / Q000276:immunology* / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D007700:Kinetics; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015850:Interleukin-6; D011994:Recombinant Proteins; D016899:Interferon-beta; D007371:Interferon-gamma